Gastrointestinal tract
AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC
May 31, 2024Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study
May 21, 2024Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis
Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …
EnteroBiotix begins phase 2 trial of IBS treatment
April 3, 2024Research and Development EnteroBiotix, Gastrointestinal tract, IBS, irritable bowel syndrome
EnteroBiotix has announced that it has dosed the first patient in its multi-centre, randomised, double-blind, placebo controlled clinical trial, which …
Sosei Heptares doses first patient in trial for inflammatory bowel disease treatment
March 21, 2024Research and Development Gastrointestinal tract, Sosei Heptares, clinical trial, inflammatory bowel disease, phase 1 trial
Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
February 20, 2024Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …
Ocelot Bio gains FDA ODD for OCE-205 for ascites treatment
December 21, 2023Research and Development Gastrointestinal tract, Ocelot Bio, ascites
Ocelot Bio has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to OCE-205 …
Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
November 23, 2023Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b …
FDA approves Phathom Pharmaceuticals’ Voquezna for erosive GERD
November 3, 2023Medical Communications Erosive GERD, FDA, Gastrointestinal tract, Phathom Pharmaceuticals, Voquezna
Phathom Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Voquenza (vonoprazan) tablets 10mg and 20mg, …
Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment
October 27, 2023Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …
Roche announces acquisition of Telavant
October 23, 2023Business Services Gastrointestinal tract, Roche, Telavant
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
October 4, 2023Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …
Alfasigma to acquire Intercept Pharmaceuticals for $19 per share
September 27, 2023Business Services Alfasigma, Gastrointestinal tract, acquisition
Alfasigma and Intercept Pharmaceuticals have announced that they have entered into a definitive merger agreement, meaning Alfasigma will acquire Intercept …
Research shows neonatal stem cells could be used as treatment for Crohn’s disease
July 31, 2023Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal
Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …
OSE Immunotherapies’ UC drug gets DSMB positive recommendation
July 6, 2023Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis
French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …
Amsterdam UMC’s new drug doubles remission rates in patients with ulcerative colitis
July 4, 2023Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis
A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
